Breaking Down Angion Biomedica Corp. (ANGN) Financial Health: Key Insights for Investors

Curious whether Angion Biomedica Corp. is a turnaround bet or a cautionary tale? Between a reported net loss of $51.9 million for the year ended December 31, 2024 and an accumulated deficit that swelled to roughly $215.9 million as of June 30, 2025, the company's financial picture is stark, especially given just $22.1 million in cash and cash equivalents on hand at that same date; add a November 26, 2025 intrinsic valuation of -$33.90 per share and a startling trailing return on equity of -7,534.48% (Nov. 2025) into the mix, alongside pivotal corporate moves like the 1-for-10 reverse split in June 2023, the discontinued JUNIPER Phase 2 trial, and the January 2023 merger agreement with Elicio Therapeutics - all of which have driven dilution, volatility and deep losses-read on to dissect revenue, profitability, liquidity, valuation and risk in granular detail.

Angion Biomedica Corp. (ANGN) Revenue Analysis

• Net loss (FY): $51.9 million for year ended December 31, 2024 vs. $35.2 million for year ended December 31, 2023.
• Accumulated deficit: $194.1 million as of December 31, 2024.
• Cash and cash equivalents: $22.1 million as of June 30, 2025.

• June 2022: Discontinued JUNIPER Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases - program setback reducing near-term value drivers.
• January 2023: Entered definitive merger agreement with Elicio Therapeutics - strategic transaction that may alter pipeline and financing profile.
• June 2023: Executed a 1-for-10 reverse stock split to regain Nasdaq minimum bid price compliance - equity consolidation affecting float and shareholder base.

• Clinical readouts and portfolio reshaping post-Elicio merger
• Ability to secure additional capital before cash runway exhaustion
• Potential licensing, partnership or milestone revenues from remaining programs

Angion Biomedica Corp. (ANGN) - Profitability Metrics

Key profitability indicators for Angion Biomedica Corp. (ANGN) reflect the company's clinical-stage profile: ongoing operating losses, a large accumulated deficit, and extreme volatility in return on equity driven by negative equity and historical outliers. For more on company background and business model, see Angion Biomedica Corp. (ANGN): History, Ownership, Mission, How It Works & Makes Money.

• Loss trajectory: recent interim results show continued cash consumption (-$21.8M over six months in 2025) consistent with prior multi‑quarter losses (-$69.5M over nine months in 2021, +36% year‑over‑comparable increase reported then).
• ROE distortion: the extremely negative ROE (-7,534.48% as of Nov 2025) reflects a small or negative equity denominator rather than typical operating performance comparisons.
• Historic variance: the 10‑year mean ROE of 57.83% indicates prior periods with strong ROE outliers, but mean and current are not aligned-investors should treat the mean cautiously.
• Balance sheet strain: an accumulated deficit of ~$215.9M as of June 30, 2025 underscores the need for ongoing financing to fund trials and operations.
• Profitability outlook: net profit margin remains negative; any path to positive margins depends on successful commercialization or partnering/licensing events.

Angion Biomedica Corp. (ANGN) - Debt vs. Equity Structure

• Primary financing to date: net proceeds of $205.2 million from securities issuances (common stock, convertible preferred stock, and convertible notes).
• Notable public raise: $117 million initial public offering (IPO) and concurrent private placement closed in February 2021.
• Operating performance: net loss of $21.8 million for the six months ended June 30, 2025, contributing to an accumulated deficit of $215.9 million as of that date.
• Capital instruments: combination of common stock issuances, convertible preferred shares, and convertible notes have been used to fund operations.
• Shareholder impact: repeated equity and convertible financings have resulted in significant dilution for existing shareholders.

• Risk considerations related to the structure:
  • Equity-heavy financing reduces leverage risk but increases dilution and reduces per-share economic interest for existing investors.
  • Convertibles create potential future dilution if converted, and may carry anti-dilution provisions or conversion features that affect equity value.
  • Ongoing operating losses and a growing accumulated deficit increase reliance on capital markets for future funding.
• Investor takeaway: assess dilution sensitivity (outstanding convertibles, warrants, authorized shares) and the company's runway assumptions tied to future financings.

Angion Biomedica Corp. (ANGN) - Liquidity and Solvency

• Cash and cash equivalents (June 30, 2025): $22.1 million
• Net loss (six months ended June 30, 2025): $21.8 million
• Accumulated deficit (June 30, 2025): ~$215.9 million
• Material dependence on financing activities (common stock issuance, convertible notes)
• Reverse stock split: 1-for-10 (June 2023) to regain Nasdaq minimum bid price compliance
• Significant dilution experienced by existing shareholders due to financing

Angion Biomedica Corp. (ANGN) - Valuation Analysis

• Intrinsic value (DCF-based estimate, 11/26/2025): -$33.90 per share.
• Market price (11/26/2025): $1.00 per share - implying the market price is materially higher than intrinsic value.
• Relative valuation (P/E multiples framework): implied fair price of -$17.04 per share.
• Peter Lynch fair-value estimate: -$24.59 per share.
• Primary drivers: accumulated deficit, ongoing net losses, and financing/dilution from equity raises.

• Negative valuation outcomes arise when forecasted free cash flows and earnings remain persistently negative; DCF and earnings-multiple approaches will produce negative per-share valuations when projected undiscounted future earnings are insufficient to offset the present value of invested capital.
• Accumulated deficit: a large negative shareholders' equity component that signals cumulative historical losses and limits textbook textbook-based valuation multipliers focused on earnings or book value.
• Reliance on financing: repeated capital raises increase share count (dilution) and raise the cost of capital, both compressing per-share intrinsic value estimates.

Angion Biomedica Corp. (ANGN) - Risk Factors

• Operating losses: Net loss of $21.8 million for the six months ended June 30, 2025.
• Accumulated deficit: Approximately $215.9 million as of June 30, 2025.
• Financing dependence: Ongoing funding via issuance of common stock and convertible notes to sustain operations.
• Shareholder dilution: Repeated financings have materially diluted existing shareholders' equity.
• Stock volatility and market actions: 36% share-price decline to $1.0950 in June 2022 following the discontinuation of a clinical trial; 1-for-10 reverse stock split executed in June 2023 to regain Nasdaq compliance.

• Liquidity risk: Continued negative cash flows necessitate additional capital raises; inability to obtain financing on acceptable terms could force program delays, asset sales or restructuring.
• Market and regulatory risk: Clinical setbacks (as seen in 2022) can trigger abrupt market repricing and funding challenges.
• Equity dilution risk: Future equity or convertible financings expected to further dilute existing holders unless offset by value-creating clinical/strategic milestones.
• Nasdaq compliance risk: Historical minimum bid price noncompliance required a reverse split; further listings risk remains if share price declines recur.

Angion Biomedica Corp. (ANGN) - Growth Opportunities

• Merger counterparty: Elicio Therapeutics (privately held)
• Combined public name: Elicio Therapeutics (expected)
• Expected Nasdaq ticker: ELTX
• Headquarters for combined company: Boston, MA
• Anticipated timing: expected to close in the first quarter of 2023, subject to customary closing conditions
• Strategic rationale: expand product pipeline and enhance shareholder value through complementary assets and combined expertise